Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

Toni K. Choueiri, Anne Plantade, Paul Elson, Sylvie Negrier, Alain Ravaud, Stephane Oudard, Ming Zhou, Brian I. Rini, Ronald M. Bukowski, Bernard Escudier

Research output: Contribution to journalArticle

320 Citations (Scopus)

Abstract

Purpose: Sunitinib and sorafenib are novel tyrosine kinase inhibitors (TKIs) that have shown significant clinical activity in metastatic clear cell renal cell carcinoma (RCC). The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated. Patients and Methods: Clinical features at study entry and treatment outcomes were evaluated in patients with metastatic papillary RCC (PRCC) and chromophobe RCC (ChRCC) who received either sunitinib or sorafenib as their initial TKI treatment in five US and French institutions. Response rate and survival were documented. Fisher's exact test was used for categoric variables, and the Kaplan-Meier method was used to estimate survival. Results: Fifty-three patients were included. The number of patients with papillary and chromophobe histologies was 41 (77%) and 12 (23%), respectively. Response rate, progression-free survival (PFS) time, and overall survival time for the entire cohort were 10%, 8.6 months, and 19.6 months, respectively. Three (25%) of 12 ChRCC patients achieved a response (two patients treated with sorafenib and one treated with sunitinib), and PFS was 10.6 months. Two (4.8%) of 41 PRCC patients achieved a response (both patients were treated with sunitinib). PFS for the whole cohort was 7.6 months. Sunitinib-treated PRCC patients had a PFS of 11.9 months compared with 5.1 months for sorafenib-treated patients (P < .001). Conclusion: Patients with PRCC and ChRCC may have prolonged PFS from sunitinib and sorafenib, although clinical responses remain overall low in PRCC. Additional prospective trials with these agents in non-clear cell RCC will further clarify their use in the future.

Original languageEnglish (US)
Pages (from-to)127-131
Number of pages5
JournalJournal of Clinical Oncology
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Renal Cell Carcinoma
Disease-Free Survival
Protein-Tyrosine Kinases
Histology
sunitinib
sorafenib
Survival
Survival Rate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Choueiri, T. K., Plantade, A., Elson, P., Negrier, S., Ravaud, A., Oudard, S., ... Escudier, B. (2008). Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Journal of Clinical Oncology, 26(1), 127-131. https://doi.org/10.1200/JCO.2007.13.3223

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. / Choueiri, Toni K.; Plantade, Anne; Elson, Paul; Negrier, Sylvie; Ravaud, Alain; Oudard, Stephane; Zhou, Ming; Rini, Brian I.; Bukowski, Ronald M.; Escudier, Bernard.

In: Journal of Clinical Oncology, Vol. 26, No. 1, 01.01.2008, p. 127-131.

Research output: Contribution to journalArticle

Choueiri, TK, Plantade, A, Elson, P, Negrier, S, Ravaud, A, Oudard, S, Zhou, M, Rini, BI, Bukowski, RM & Escudier, B 2008, 'Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma', Journal of Clinical Oncology, vol. 26, no. 1, pp. 127-131. https://doi.org/10.1200/JCO.2007.13.3223
Choueiri, Toni K. ; Plantade, Anne ; Elson, Paul ; Negrier, Sylvie ; Ravaud, Alain ; Oudard, Stephane ; Zhou, Ming ; Rini, Brian I. ; Bukowski, Ronald M. ; Escudier, Bernard. / Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 1. pp. 127-131.
@article{1327ee919ff24abaacd7b3408848a16e,
title = "Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma",
abstract = "Purpose: Sunitinib and sorafenib are novel tyrosine kinase inhibitors (TKIs) that have shown significant clinical activity in metastatic clear cell renal cell carcinoma (RCC). The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated. Patients and Methods: Clinical features at study entry and treatment outcomes were evaluated in patients with metastatic papillary RCC (PRCC) and chromophobe RCC (ChRCC) who received either sunitinib or sorafenib as their initial TKI treatment in five US and French institutions. Response rate and survival were documented. Fisher's exact test was used for categoric variables, and the Kaplan-Meier method was used to estimate survival. Results: Fifty-three patients were included. The number of patients with papillary and chromophobe histologies was 41 (77{\%}) and 12 (23{\%}), respectively. Response rate, progression-free survival (PFS) time, and overall survival time for the entire cohort were 10{\%}, 8.6 months, and 19.6 months, respectively. Three (25{\%}) of 12 ChRCC patients achieved a response (two patients treated with sorafenib and one treated with sunitinib), and PFS was 10.6 months. Two (4.8{\%}) of 41 PRCC patients achieved a response (both patients were treated with sunitinib). PFS for the whole cohort was 7.6 months. Sunitinib-treated PRCC patients had a PFS of 11.9 months compared with 5.1 months for sorafenib-treated patients (P < .001). Conclusion: Patients with PRCC and ChRCC may have prolonged PFS from sunitinib and sorafenib, although clinical responses remain overall low in PRCC. Additional prospective trials with these agents in non-clear cell RCC will further clarify their use in the future.",
author = "Choueiri, {Toni K.} and Anne Plantade and Paul Elson and Sylvie Negrier and Alain Ravaud and Stephane Oudard and Ming Zhou and Rini, {Brian I.} and Bukowski, {Ronald M.} and Bernard Escudier",
year = "2008",
month = "1",
day = "1",
doi = "10.1200/JCO.2007.13.3223",
language = "English (US)",
volume = "26",
pages = "127--131",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

AU - Choueiri, Toni K.

AU - Plantade, Anne

AU - Elson, Paul

AU - Negrier, Sylvie

AU - Ravaud, Alain

AU - Oudard, Stephane

AU - Zhou, Ming

AU - Rini, Brian I.

AU - Bukowski, Ronald M.

AU - Escudier, Bernard

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Purpose: Sunitinib and sorafenib are novel tyrosine kinase inhibitors (TKIs) that have shown significant clinical activity in metastatic clear cell renal cell carcinoma (RCC). The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated. Patients and Methods: Clinical features at study entry and treatment outcomes were evaluated in patients with metastatic papillary RCC (PRCC) and chromophobe RCC (ChRCC) who received either sunitinib or sorafenib as their initial TKI treatment in five US and French institutions. Response rate and survival were documented. Fisher's exact test was used for categoric variables, and the Kaplan-Meier method was used to estimate survival. Results: Fifty-three patients were included. The number of patients with papillary and chromophobe histologies was 41 (77%) and 12 (23%), respectively. Response rate, progression-free survival (PFS) time, and overall survival time for the entire cohort were 10%, 8.6 months, and 19.6 months, respectively. Three (25%) of 12 ChRCC patients achieved a response (two patients treated with sorafenib and one treated with sunitinib), and PFS was 10.6 months. Two (4.8%) of 41 PRCC patients achieved a response (both patients were treated with sunitinib). PFS for the whole cohort was 7.6 months. Sunitinib-treated PRCC patients had a PFS of 11.9 months compared with 5.1 months for sorafenib-treated patients (P < .001). Conclusion: Patients with PRCC and ChRCC may have prolonged PFS from sunitinib and sorafenib, although clinical responses remain overall low in PRCC. Additional prospective trials with these agents in non-clear cell RCC will further clarify their use in the future.

AB - Purpose: Sunitinib and sorafenib are novel tyrosine kinase inhibitors (TKIs) that have shown significant clinical activity in metastatic clear cell renal cell carcinoma (RCC). The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated. Patients and Methods: Clinical features at study entry and treatment outcomes were evaluated in patients with metastatic papillary RCC (PRCC) and chromophobe RCC (ChRCC) who received either sunitinib or sorafenib as their initial TKI treatment in five US and French institutions. Response rate and survival were documented. Fisher's exact test was used for categoric variables, and the Kaplan-Meier method was used to estimate survival. Results: Fifty-three patients were included. The number of patients with papillary and chromophobe histologies was 41 (77%) and 12 (23%), respectively. Response rate, progression-free survival (PFS) time, and overall survival time for the entire cohort were 10%, 8.6 months, and 19.6 months, respectively. Three (25%) of 12 ChRCC patients achieved a response (two patients treated with sorafenib and one treated with sunitinib), and PFS was 10.6 months. Two (4.8%) of 41 PRCC patients achieved a response (both patients were treated with sunitinib). PFS for the whole cohort was 7.6 months. Sunitinib-treated PRCC patients had a PFS of 11.9 months compared with 5.1 months for sorafenib-treated patients (P < .001). Conclusion: Patients with PRCC and ChRCC may have prolonged PFS from sunitinib and sorafenib, although clinical responses remain overall low in PRCC. Additional prospective trials with these agents in non-clear cell RCC will further clarify their use in the future.

UR - http://www.scopus.com/inward/record.url?scp=37849001813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849001813&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.13.3223

DO - 10.1200/JCO.2007.13.3223

M3 - Article

C2 - 18165647

AN - SCOPUS:37849001813

VL - 26

SP - 127

EP - 131

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -